Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
{{output}}
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It ... ...
